Ally Bridge Group’s Praxis Precision Medicines PRAX Stock Holding History

Ally Bridge Group’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$5.3M	–	28
2025 Q3	$5.3M	Buy	+100,000	New	+$4.85M	3.23%	13

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Ally Bridge Group's PRAX Position: Q2 2026 in Review

Ally Bridge Group sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 32,810 shares — an estimated $10.6M sold.

Ally Bridge Group first reported a position in PRAX in Q4 2022 and held it in 12 quarters. The position peaked at $10.6M in Q1 2026. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Ally Bridge Group reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
Ally Bridge Group sold 32,810 Praxis Precision Medicines shares in Q2 2026, an estimated $10.6M.
Ally Bridge Group first reported a position in Praxis Precision Medicines in Q4 2022 and held it in 12 quarters.
Ally Bridge Group's Praxis Precision Medicines position peaked at $10.6M in Q1 2026.
310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.